促进疫苗研究:TRANSVAC疫苗基础设施的16年历程。

IF 5.2 3区 医学 Q1 IMMUNOLOGY
Vaccines Pub Date : 2024-12-22 DOI:10.3390/vaccines12121446
William Martin, Catarina Luís, Stefan Jungbluth, Monika Slezak, Frank A W Verreck, Holger Spiegel, Carlos A Guzman, António Roldão, Manuel J T Carrondo, Peter Van der Ley, Joaquim Segalés, Hazel M Dockrell, Mei Mei Ho, Gabriel K Pedersen, Maria Lawrenz, Ole F Olesen
{"title":"促进疫苗研究:TRANSVAC疫苗基础设施的16年历程。","authors":"William Martin, Catarina Luís, Stefan Jungbluth, Monika Slezak, Frank A W Verreck, Holger Spiegel, Carlos A Guzman, António Roldão, Manuel J T Carrondo, Peter Van der Ley, Joaquim Segalés, Hazel M Dockrell, Mei Mei Ho, Gabriel K Pedersen, Maria Lawrenz, Ole F Olesen","doi":"10.3390/vaccines12121446","DOIUrl":null,"url":null,"abstract":"<p><p>TRANSVAC represents a long-running effort to accelerate the development of novel vaccines by integrating institutions from across Europe under a single collaborative framework. This initiative has empowered the global vaccine community since 2009 including contributing toward the development and optimization of vaccine candidates as well as the provision of new adjuvants, research protocols, and technologies. Scientific services were provided in support of 88 different vaccine development projects, and 400 professionals attended TRANSVAC training events on various vaccine-related topics. Here, we review the accomplishments of the TRANSVAC consortia and analyze the continued needs of academic and industrial vaccine developers in Europe. The findings highlight the benefits of coordination across different sectors, both through research infrastructures such as TRANSVAC and other mechanisms, to address the current and future global health challenges and ensure that European vaccine developers have the support required to successfully compete in the global market.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"12 12","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680270/pdf/","citationCount":"0","resultStr":"{\"title\":\"Boosting Vaccine Research: The 16-Year Journey of TRANSVAC Vaccine Infrastructure.\",\"authors\":\"William Martin, Catarina Luís, Stefan Jungbluth, Monika Slezak, Frank A W Verreck, Holger Spiegel, Carlos A Guzman, António Roldão, Manuel J T Carrondo, Peter Van der Ley, Joaquim Segalés, Hazel M Dockrell, Mei Mei Ho, Gabriel K Pedersen, Maria Lawrenz, Ole F Olesen\",\"doi\":\"10.3390/vaccines12121446\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>TRANSVAC represents a long-running effort to accelerate the development of novel vaccines by integrating institutions from across Europe under a single collaborative framework. This initiative has empowered the global vaccine community since 2009 including contributing toward the development and optimization of vaccine candidates as well as the provision of new adjuvants, research protocols, and technologies. Scientific services were provided in support of 88 different vaccine development projects, and 400 professionals attended TRANSVAC training events on various vaccine-related topics. Here, we review the accomplishments of the TRANSVAC consortia and analyze the continued needs of academic and industrial vaccine developers in Europe. The findings highlight the benefits of coordination across different sectors, both through research infrastructures such as TRANSVAC and other mechanisms, to address the current and future global health challenges and ensure that European vaccine developers have the support required to successfully compete in the global market.</p>\",\"PeriodicalId\":23634,\"journal\":{\"name\":\"Vaccines\",\"volume\":\"12 12\",\"pages\":\"\"},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2024-12-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680270/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccines\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/vaccines12121446\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/vaccines12121446","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

TRANSVAC代表了一项长期努力,通过将欧洲各地的机构整合在一个单一的合作框架下,加速新型疫苗的开发。自2009年以来,这一举措增强了全球疫苗界的能力,包括促进候选疫苗的开发和优化,以及提供新的佐剂、研究方案和技术。为支持88个不同的疫苗开发项目提供了科学服务,400名专业人员参加了TRANSVAC关于各种疫苗相关主题的培训活动。在这里,我们回顾了TRANSVAC联盟的成就,并分析了欧洲学术和工业疫苗开发商的持续需求。这些发现强调了通过TRANSVAC等研究基础设施和其他机制在不同部门之间进行协调的好处,以应对当前和未来的全球卫生挑战,并确保欧洲疫苗开发人员获得在全球市场上成功竞争所需的支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Boosting Vaccine Research: The 16-Year Journey of TRANSVAC Vaccine Infrastructure.

TRANSVAC represents a long-running effort to accelerate the development of novel vaccines by integrating institutions from across Europe under a single collaborative framework. This initiative has empowered the global vaccine community since 2009 including contributing toward the development and optimization of vaccine candidates as well as the provision of new adjuvants, research protocols, and technologies. Scientific services were provided in support of 88 different vaccine development projects, and 400 professionals attended TRANSVAC training events on various vaccine-related topics. Here, we review the accomplishments of the TRANSVAC consortia and analyze the continued needs of academic and industrial vaccine developers in Europe. The findings highlight the benefits of coordination across different sectors, both through research infrastructures such as TRANSVAC and other mechanisms, to address the current and future global health challenges and ensure that European vaccine developers have the support required to successfully compete in the global market.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Vaccines
Vaccines Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
8.90
自引率
16.70%
发文量
1853
审稿时长
18.06 days
期刊介绍: Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信